我国奶牛重大疾病防治研究进展 Major Disease Research Progress on Cows in China 杨志强 研究员/博导 国家现代农业产业技术奶牛体系疾病控制研究室 中国农业科学院兰州畜牧与兽药研究所 2010年6月 中国 青岛
1 ( Preface ) 1300 200
2 33 74% 40 10 30% 30 40 50% 25
3
Research Progress on Mastitis
25kg 4000 kg % 13.8 5.3 3.6 2.7 0.9 4.3 0.8 8.2 10.8 2.2 6.1 3.0 3.1 1.5 1.0 22.2
1 1 2 3
150 20 20 (Streptococcus agalactiae) (Streptococcus dysgalactiae ) (Staphylococcus arueus) (Mycoplasma) Escherichia coli (Streptococcus uberis) (Klabsiella) (Pseudomonas aeruginosa) ) (Enterobacter ( aerogenes) ) (Proteus) (Loaglase negative) (Streptococcus environmental) Actinobacillus suppurative Corynebacterium bovis Epiphyte (Microzyme)
2 1 2 3 4
3 1 2 3
8
1 1 2 3 4
2 : :
1 Somatic Cell Counts SCC 50 /ml
2 California Mastitis Test CMT 1957 Scalm Norlander N l CMT DNA DNA
3 LMT 4 4 2 ml 2 ml
4 ph ph 5 6 B.M.T ( ) MT ( ) 0.4 ml 3% 0.3 3mL 1cm 1 ; 7 N.M.T ( ) MT ( ) 3mL 0.5 ml 10s ( ) 8
( ) 1 2 3 4 5 6
1 100-300 3% 10-20mL 40-60mL 80% 60% 100% 90%
2 ( ) ) 250g,, 1,3 d 50ml 4, 1 3-4 153, 140, 91.5 %, 13l, 85.6 % 66, 84.3 %, 95.3 %
1 3 126, 94.44 %, 40% 34,100% 38, 34, 2-3 2, 8.9 %
2 124, 88. 4 %, 95.8 95 8 %, 83. 6 % 125, 84 %,, 86.4% 902 93, 94.6 %
4 2 3 24 h 7d 15 (20 ) 100% ( ) 85.60%-95.83% 87.72%
5 MASTIVACS I J-5
1 Watson (W79) (
Lulzim Shkreta DNA DNA FnBP Dl2l-34 D320-33 C1fA aa221-550 (pci- D1D3-IRES-C1fA)
2 2 IgG1 IgA g g Finch M J 0140J 0140J C221
Poutrel - Michael (GapC) ( GapC GapC GapC
3 (LPS) (LPS) Ag A Ag E Coli J5 O- A G- Ig E.coli.J5
4 3 1, 5ml 49.22%-59.86% 6
6
1
2 1-2
3 50
4 5 6
( Research Progress on Endometritis )
106
1. 2. 3. 5. 4. 6. 7. 8. 9.
1 2 3 38 C 1
1 Yautcaun 2mL 2mL4 NaOH 2 ph 1-2mL ph ph 7.5-8.5 7 585 7 3 2mL 5 1mL 2min 4 30-60min
1 98.6 2
1 2 3 4 5 6
1 250 IU 200mL 250 IU 200 L 0.5 7d 1 80.7 10 20mL 2g 0.5g 7-10d 2-3 71.5
2 94.55 94 84.94% 10mL( ml 3g) 1.5g 1g 20mL 93.1 72.4
1 3 720 92.9 42 95 57 75.4
2 2 100 1 3-4 1 85.7% 85.7% 98.63% 3 50 3 1 3 1
4 20 5-7 3 88.24% 4-5 89.5 50ml 1 3 80.0
5 20 3~4 2~3 64.7 13 53.8 0.25~0.5 40ml 160 IU 60
1
2
3 4 14-28 5
( Research Progress on Feet and Leg Disease )
1 2 3
4 5 ( ) 6
( ) 1 2 3 4 5 6
0.1% 3 3 1 100-200 5-10 1 1 3-7 80 2-3 80 2-3
2 60 6 30 30 15 86% 86% 100 100 50 20 100 50 50 50 20 20 20 20 20 91%
3 100 50 30 200 40 20 40 20 1 2 50 50 60 100-200 5-10 1 1 3-7
4 30 ml 300 5 ml,, 0.5% 10-20mL 320 IU
5 6 80% A E E II2
1 6,,, 2,,,, 5-7, 2-4s, 3 ( )
1,, 2 3 1-2
4 5 6
1 ( Situation and Perspective )
2
3
4
Thank you!